TargetMol

Bryodulcosigenin

Product Code:
 
TAR-TN1455
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TN1455-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1455-5mg5mg£298.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1455-1mL1 mL * 10 mM (in DMSO)£329.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1455-10mg10mg£409.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1455-25mg25mg£623.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1455-50mg50mg£839.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1455-100mg100mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Bryodulcosigenin has anti-inflammatory effect, it shows potent inhibitory effects on EBV-EA induction.
CAS:
4965-97-3
Formula:
C30H50O4
Molecular Weight:
474.726
Pathway:
Immunology/Inflammation
Purity:
0.9924
SMILES:
[H][C@@]12CC[C@H](O)C(C)(C)C1=CC[C@@]1([H])[C@]3(C)CC[C@H]([C@H](C)CCC(O)C(C)(C)O)[C@@]3(C)CC(=O)[C@@]21C
Target:
Immunology/Inflammation related

References

Anti-inflammatory and anti-tumor-promoting effects of cucurbitane glycosides from the roots of Bryonia dioica.J Nat Prod. 2002 Feb;65(2):179-83.